RSNA 2021 Molecular Imaging Preview

PET/MRI assesses ankylosing spondylitis treatment

By Will Morton, staff writer

Thursday, December 2 | 9:30 a.m.-10:00 a.m. | SSNMMI07-4 | Room E450B
F-18 sodium fluoride PET/MRI (F-18 NaF PET/MRI) of osteoblastic activity in ankylosing spondylitis patients can assess the effects of anti-tumor necrosis factor (TNF) therapy, according to German researchers presenting in this session.

Diagnostic and interventional radiologist Dr. Nils-Martin Bruckmann of the University of Dusseldorf will discuss details of a study in 11 men and five women with clinically active radiographic axial spondyloarthritis (r-axSpA). The researchers performed F-18 NaF PET/MRI scans of the sacroiliac joint and whole spine in patients at baseline and at time points up to six months following anti-TNF therapy.

Three independent readers evaluated all images for inflammation (bone marrow edema) and structural lesions. F-18 NaF uptake was recorded on the level of sacroiliac joint quadrants (SIJ-Q) and vertebral quadrants (VQ). The researchers analyzed a total of 128 SIJ-Qs and 920 VQs at each time point.

At baseline, F-18 NaF uptake was found in 96% of sacroiliac joint quadrants with bone marrow edema, 94.2% of quadrants with sclerosis, and 88.3% with fat lesions. At follow-up, there was a significant decrease in F-18 NaF uptake, with uptake in 65.3% of sacroiliac joint quadrants with bone marrow edema, 33.8% with sclerosis, and 24.5% with fat lesions.

The findings support the early initiation of anti-inflammatory treatment for the prevention of radiographic progression in axial spondyloarthritis, the group noted.

Find out more about the study by attending this session on Thursday morning.

Last Updated np 11/19/2021 11:58:31 AM